XML 58 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information
12 Months Ended
Dec. 29, 2017
Segment Reporting [Abstract]  
Segment Information
SEGMENT INFORMATION
We operate in one business segment which focuses on discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Enterprise-wide disclosures about product sales, revenues from major customers, revenues and long-lived assets by geographic area are presented below.
Net product revenues by product were as follows (dollars in thousands): 
 
Year Ended December 31,
 
2017
 
2016
 
2015
CABOMETYX
$
324,000

 
$
93,481

 
$

COMETRIQ
25,008

 
41,894

 
34,158

Net product revenues
$
349,008

 
$
135,375

 
$
34,158


The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:
 
Year Ended December 31,
 
2017
 
2016
 
2015
Diplomat Specialty Pharmacy
18
%
 
33
%
 
83
%
Caremark L.L.C.
16
%
 
9
%
 
%
Ipsen
15
%
 
17
%
 
%
Accredo Health, Incorporated
11
%
 
9
%
 
%
Affiliates of McKesson Corporation
11
%
 
7
%
 
%

Revenues earned by geographic region were as follows (dollars in thousands):
 
Year Ended December 31,
 
2017
 
2016
 
2015
U.S.
$
367,906

 
$
140,709

 
$
33,869

Europe
69,792

 
35,745

 
3,303

Rest of the world
14,779

 
15,000

 


Net product revenues are attributed to regions based on ship-to location and Collaboration revenues are attributed to regions based on the location of the collaboration partner.
We recorded a $0.2 million loss, a $0.2 million loss and a $0.1 million gain relating to foreign exchange fluctuations for the years ended December 31, 2017, 2016 and 2015, respectively.
All of our long-lived assets are located in the U.S.